latest blog entries
Loading...
Branding...
latest headlines for company on cafepharma
CNBC
Sat, 01/12/13 - 11:33 am
Motley Fool
Tue, 09/04/12 - 11:08 am
Seeking Alpha
Mon, 06/25/12 - 11:22 am
Seeking Alpha
Fri, 05/18/12 - 5:18 pm
TheStreet.com
Tue, 02/14/12 - 12:29 pm
Seeking Alpha
Sun, 12/11/11 - 3:40 pm
tags: Acorda Therapeutics, Amgen, BioSpecifics Technologies, Cadence Pharmaceuticals, Charles River Laboratories, Chelsea Therapeutics, Dendreon, Enzon, Insmed, Jazz Pharmaceuticals, Momenta, Nabi, Pacific Biosciences, PDL Biopharma, Sangamo BioSciences, ShangPharma, Sinovac Biotech, Transcept, Vanda, ViroPharma
Investor's Business Daily
Sun, 10/09/11 - 3:51 pm
tags: Acorda Therapeutics, Biomarin, Cepheid, Genomic Health, Supergen
Seeking Alpha
Sun, 09/18/11 - 12:02 pm
Seeking Alpha
Tue, 08/30/11 - 8:36 am
Seeking Alpha
Wed, 08/03/11 - 11:08 am
tags: Abbott Laboratories, Acorda Therapeutics, Adeona, Biogen Idec, Elan, M&A
Seeking Alpha
Thu, 07/21/11 - 12:21 pm
TheStreet.com
Mon, 07/18/11 - 10:03 am
Seeking Alpha
Sat, 07/16/11 - 11:39 am
tags: Acorda Therapeutics, Dendreon, Exelixis, InterMune, Savient
Minyanville
Tue, 07/05/11 - 9:58 am
Last 30 twitter posts
- Potential Acorda Therapeutics $ACOR Trade Has $29.33 Breakeven ( t.co/sDUubAF0IB )
- Additional Patent for Acorda's Ampyra - Analyst Blog: Acorda Therapeutics announced th... t.co/Dv2hqkhZa1 t.co/dpqXQbq6Ds
- "Our industry is moving to a branded specialty pipeline" -Kent Rogers, former VP of managed markets at Acorda Therapeutics
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Du... t.co/gi7Ww2JtCb
- #Legal News. #ALM Names “Best #Legal Departments” Winners: Acorda Therapeutics, Bristol-Myers Squibb, Caesars, CSU t.co/pGBRVItv5E
- Acorda Therapeutics anuncia la publicación de nuevos datos sobre el impacto de la deficiencia de movilidad debido a la esclerosis múltiple…
- RT @Briefingcom: $ACOR: Acorda Therapeutics announces publication of new data on impact of mobility impairment due to multiple... t.co/UG4epijXre
- CORRECTING and REPLACING Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairmen... t.co/zSNpEQ0IcM
- $ACOR: Acorda Therapeutics announces publication of new data on impact of mobility impairment due to multiple... t.co/UG4epijXre
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/2IRErpr2c8
- $ACOR Acorda Therapeutics Inc Files 8-K : Other Events, Financial Statements and E.. t.co/y1g1bkCBp1
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/9tnvFdApEL
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/NFMWG1pzcY
- Acorda Therapeutics - Acorda Therapeutics Inc. was established in March 1995 to develop therapeutic products for s... t.co/dVlIZ736es
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/n3C1bSsi1I
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/KWpbTcQVY9 #...
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/9XrtVw1y19
- Acorda Therapeutics Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis t.co/OZPaBA0CUI
- RT @shelleypetersen: Acorda gains additional US patent for Ampyra dosage range t.co/hnTFdKzrlQ #healthinnovations #pharma #fda #medical #research #doctor
- Acorda gains additional US patent for Ampyra dosage range t.co/hnTFdKzrlQ #healthinnovations #pharma #fda #medical #research #doctor
- Pharma News: Acorda obtains additional US patent for ampyra: Acorda Therapeutics has obtained additional US pa... t.co/luG4YAKkbR
- Pharma News: Acorda obtains additional US patent for ampyra - Acorda Therapeutics has obtained additional US paten... t.co/Eoq5EeMNP5
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA ... - EON: Enhanced Online News (p... t.co/qGnm0uTCKr
- Acorda Therapeutics Announces Issuance of Additional U.S. Patent... t.co/LQ62y3oGQD via @EONpr
- Patent Acorda Therapeutics Announces Issuance of Additional US Patent for AMPYRA ...: 8,440,703 (“the '703 ... t.co/3uE2GdiEk8 IP
- Acorda Therapeutics (ACOR -1%) is issued a patent for Amprya entitled "Methods of Using Sustained Rel... t.co/VQJnKQjNk9 $ACOR
- t.co/RDfpgq7d2n Acorda Therapeutics Announces Issuance of t.co/EdYNeSvcVn #engineer #climatehawks #jackpot #oceans #finance
- t.co/RDfpgq7d2n Acorda Therapeutics Announces Issuance of t.co/EdYNeSvcVn #amazon #savetigersnow #doctors #startups #biodiesel
- $heff: $ACOR..$32.94..Acorda Therapeutics Announces New US Patent for AMPYRA. t.co/IfGYQXe1fv
- RT @Benzinga: Acorda Therapeutics Announces New US Patent for AMPYRA t.co/Fjj9rLOqLn $ACOR
Latest Health Message Board Posts
... go and they wanted to confirm my shipping address. They then said my co-pay was $40/month! I confirmed my shipping information :-) Acorda Therapeutics, the maker of Ampyra, has a policy/program that ensures that no one pay more than $40 co-pay/month. Kyle
Posted by:
Nikodicreta
at
2013-01-04 06:00:00
on
medhelp.org
... Addressing Walking Impairment AMPYRA Previously Referred to as Fampridine-SR AMPYRA Expected to be Available by Prescription in March 2010 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received marketing approval from the U.S. Food ...
Posted by:
kwarendorf
at
2012-07-11 05:00:00
on
medhelp.org
For a somewhat less glowing assessment: http://industry.bnet.com/pharma/10006294/acorda-therapeutics-ms-drug-ampyra-could-stumble/ Note also that at the end of the article, they anticipate the annual price tag to be at least $10,000. sho
Posted by:
Forum Admin
at
2010-02-03 00:46:00
on
depressionforums.org
... membership, Antisense Therapeutics Ltd, BCDecker, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Pharmaceuticals, Eli Lilly, UCB; consultancy, Genentech, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Neuroscience, Teva Pharmaceuticals, Acorda, Acetilon ...
Posted by:
shoshin
at
2010-01-26 06:00:00
on
medhelp.org
... , a spokesperson for the FDA confirmed. It will be manufactured under licenses from Elan of Dublin, Ireland, and distributed by Acorda Therapeutics Inc of Hawthorne, New York. Given at doses greater than the recommended 10 mg twice a day, dalfampridine can ...
Posted by:
Lulu54
at
2010-01-23 06:00:00
on
medhelp.org




















